검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 3개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Fluorouracil (Fluorouracil) Janssen Research & Development, LL…·Muscle Invasive Bladder Carcinoma ORR 80% | ||
|---|---|---|---|
Overview Program | Fluorouracil | Tremelimumab | MK-3475 |
Overview Company | Janssen Research & Development, LLC | AstraZeneca | Merck Sharp & Dohme LLC |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | Muscle Invasive Bladder Carcinoma | Muscle Invasive Bladder Cancer | Bladder Cancer |
Overview Indication | Advanced or Metastatic Colorectal Cancer | Hepatocellular Carcinoma | Melanoma; Non-Small Cell Lung Cancer |
Overview Phase | PHASE_3 | PHASE_3 | PHASE_2 |
Overview Status | RECRUITING | RECRUITING | RECRUITING |
MoA Mechanism | inhibits GC cell proliferation and induces apoptosis by regulating cell-cycle checkpoints and inhibiting oncogenic pathway | targeting antigens like GPC3, AFP, and PD-L1, have been engineered to address antigen | — |
MoA Biomarker | biomarker for metabolic state, B-cell/TLS-associated immune features, and vulnerability to DNA damage-based t | biomarkers for dual immune checkpoint blockade remain insufficiently defined | PD-L1) combined positive |
PK/PD Half-life | — | 16.9 h | 3 h |
PK/PD Species | Mouse | Mouse | Cynomolgus monkey, NHP, Mouse |
PK/PD Animal (cat.) | Mouse | Mouse | Mouse, NHP, Monkey, In vitro |
PK/PD Experiment | PD | PD | PD |
Toxicology Species | Mouse, Human | Mouse | Cynomolgus monkey, NHP, Mouse |
Toxicology Animal (cat.) | Human | Unknown | Mouse, NHP, Monkey, In vitro |
Toxicology Major finding | thrombocytopenia, inflammation of the esophagus, stomach, and small bowel | pneumonitis, immune-mediated colitis, immune-mediated hepatitis, immune-mediated endocrinop | pneumonitis) after switching were explored |
Clinical Primary efficacy | ORR 80% | ORR 47% | ORR 38% |
Clinical ORR | 80.0% | 47% | 38% |
Clinical Result source | ClinicalTrials.gov NCT04430738 | ClinicalTrials.gov NCT02879318 | ClinicalTrials.gov NCT02444741 |
Clinical Data Tier / Score | S · 70 | B · 58 | C · 47 |
Clinical Program phase | PHASE_3 | PHASE_3 | PHASE_2 |
Clinical Clinical sync | 2026년 7월 4일 (9일 전) | 2026년 7월 4일 (9일 전) | 2026년 7월 9일 (5일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 3개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Fluorouracil (Fluorouracil) Janssen Research & Development, LL…·Muscle Invasive Bladder Carcinoma ORR 80% | ||
|---|---|---|---|
Overview Program | Fluorouracil | Tremelimumab | MK-3475 |
Overview Company | Janssen Research & Development, LLC | AstraZeneca | Merck Sharp & Dohme LLC |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | Muscle Invasive Bladder Carcinoma | Muscle Invasive Bladder Cancer | Bladder Cancer |
Overview Indication | Advanced or Metastatic Colorectal Cancer | Hepatocellular Carcinoma | Melanoma; Non-Small Cell Lung Cancer |
Overview Phase | PHASE_3 | PHASE_3 | PHASE_2 |
Overview Status | RECRUITING | RECRUITING | RECRUITING |
MoA Mechanism | inhibits GC cell proliferation and induces apoptosis by regulating cell-cycle checkpoints and inhibiting oncogenic pathway | targeting antigens like GPC3, AFP, and PD-L1, have been engineered to address antigen | — |
MoA Biomarker | biomarker for metabolic state, B-cell/TLS-associated immune features, and vulnerability to DNA damage-based t | biomarkers for dual immune checkpoint blockade remain insufficiently defined | PD-L1) combined positive |
PK/PD Half-life | — | 16.9 h | 3 h |
PK/PD Species | Mouse | Mouse | Cynomolgus monkey, NHP, Mouse |
PK/PD Animal (cat.) | Mouse | Mouse | Mouse, NHP, Monkey, In vitro |
PK/PD Experiment | PD | PD | PD |
Toxicology Species | Mouse, Human | Mouse | Cynomolgus monkey, NHP, Mouse |
Toxicology Animal (cat.) | Human | Unknown | Mouse, NHP, Monkey, In vitro |
Toxicology Major finding | thrombocytopenia, inflammation of the esophagus, stomach, and small bowel | pneumonitis, immune-mediated colitis, immune-mediated hepatitis, immune-mediated endocrinop | pneumonitis) after switching were explored |
Clinical Primary efficacy | ORR 80% | ORR 47% | ORR 38% |
Clinical ORR | 80.0% | 47% | 38% |
Clinical Result source | ClinicalTrials.gov NCT04430738 | ClinicalTrials.gov NCT02879318 | ClinicalTrials.gov NCT02444741 |
Clinical Data Tier / Score | S · 70 | B · 58 | C · 47 |
Clinical Program phase | PHASE_3 | PHASE_3 | PHASE_2 |
Clinical Clinical sync | 2026년 7월 4일 (9일 전) | 2026년 7월 4일 (9일 전) | 2026년 7월 9일 (5일 전) |
추천 비교
추천 비교